18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: A meta-analysis

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 7, 2011, Pages 1085-1093

  Xie, Peng ^a   Li, Minghuan ^a   Zhao, Hanxi ^a   Sun, Xindong ^a   Fu, Zheng ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

18F FDG; Head and neck cancer; Meta analysis; Prognosis; Standard uptake value

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANALYTICAL PARAMETERS; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG UPTAKE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METABOLISM; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; STANDARD UPTAKE VALUE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT RESPONSE; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK TUMOR; LYMPH NODE METASTASIS; MORTALITY; PATHOLOGY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79959734463     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-010-0972-y     Document Type: Article

References (55)

1. 18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20(5):1398-1404
2. Allal AS, Slosman DO, Kebdani T et al (2004) Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 59(5):1295-1300 (Pubitemid 38954050)
3. Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945-1952 (Pubitemid 38580197)
4. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567-578 (Pubitemid 43209104)
5. Brun E, Kjellén E, Tennvall J et al (2002) FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24(2):127-135 (Pubitemid 34111509)
6. 18F-FDG uptake by primary sites in patients with diffuse large B cell lymphoma in the head and neck: a pilot study. Ann Nucl Med 22(8):645-651
7. Chan SC, Chang JT, Wang HM et al (2009) Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol 45:52-58
8. 18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 15(18):5861-5868
9. Cicone F, Loose D, Deron P et al (2008) Prognostic value of FDG uptake by the bone marrow in squamous cell carcinoma of the head and neck. Nucl Med Commun 29(5):431-435 (Pubitemid 351507536)
10. Cohen EEW, Lingen MW, Vokes EE (2004) The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22:1743-1752 (Pubitemid 41079815)
11. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 80:11-20
12. Döbert N, Kovács AF, Menzel C et al (2005) The prognostic value of FDG PET in head and neck cancer. Correlation with histopathology. Q J Nucl Med Mol Imaging 49(3):253-257 (Pubitemid 41569513)
13. Garden AS, Asper JA, Morrison WH et al (2004) Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer 100:1171-1178
14. Greven KM, Williams DW 3rd, Keyes JW Jr et al (1994) Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 74(4):1355-1359 (Pubitemid 24301792)
15. Greven KM, Williams DW 3rd, McGuirt WF Sr et al (2001) Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23(11): 942-946 (Pubitemid 32977536)
16. Halfpenny W, Hain SF, Biassoni L et al (2002) FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 86(4):512-516 (Pubitemid 34185084)
17. Hoshikawa H, Mitani T, Nishiyama Y et al (2009) Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. Auris Nasus Larynx 36(2): 192-198
18. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578 (Pubitemid 350002965)
19. Kao CH, Shiau YC, Shen YY et al (2002) Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99 m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Cancer 94:1981-1986
20. Kim SY, Roh JL, Kim JS et al (2008) Utility of FDG PET in patients with squamous cell carcinomas of the oral cavity. Eur J Surg Oncol 34(2):208-215
21. Krishna SM, James S, Balaram P (2006) Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 115:85-90 (Pubitemid 41772484)
22. Kunkel M, Reichert TE, Benz P et al (2003a) Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97(4):1015-1024 (Pubitemid 36173153)
23. 18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol 39(2):170-177
24. Kunkel M, Helisch A, Reichert TE et al (2006) Clinical and prognostic value of [(18)F]FDG-PET for surveillance of oral squamous cell carcinoma after surgical salvage therapy. Oral Oncol 42(3):297-305
25. La TH, Filion EJ, Turnbull BB et al (2009) Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 74(5):1335-1341
26. Lee SW, Cho KJ, Park JH et al (2005) Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 62:1451-1457
27. Lee P, Weerasuriya DK, Lavori PW et al (2007) Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 69:328-333 (Pubitemid 47380105)
28. Lee SW, Nam SY, Im KC et al (2008) Prediction of prognosis using standardized uptake value of 2-18F- fluoro-2-deoxy-D-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 87:211-216
29. Liao CT, Chang JT, Wang HM et al (2009) Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 73(3):764-771
30. Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626-1632 (Pubitemid 47572710)
31. Linecker A, Kermer C, Sulzbacher I et al (2008) Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin 47(2):80-85 (Pubitemid 351700466)
32. Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797-805 (Pubitemid 47308659)
33. Machtay M, Natwa M, Andrel J et al (2009) Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 31(2):195-201
34. Minn H, Lapela M, Klemi PJ et al (1997) Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38(12):1907-1911 (Pubitemid 28030920)
35. Nakao K, Mochiki M, Nibu K et al (2006) Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein-Barr virus encoded small RNA1. Otolaryngol Head Neck Surg 134:639-645
36. Okada J, Oonishi H, Yoshikawa K et al (1994) FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 8(3):187-191 (Pubitemid 24290785)
37. Rege S, Safa AA, Chaiken L et al (2000) Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol 23(2):164-169
38. 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med 48(2):240-246
39. Sanghera B, Wong WL, Lodge MA et al (2005) Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun 26(10):861-867 (Pubitemid 41426547)
40. Sasaki R, Komaki R, Macapinlac H et al (2005) [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23:1136-1143 (Pubitemid 46202269)
41. Schönberger J, Rüschoff J, Grimm D et al (2002) Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 12(9):747-754
42. Schwartz DL, Rajendran J, Yueh B et al (2004) FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 130(12):1361-1367 (Pubitemid 39603296)
43. Schwarz JK, Siegel BA, Dehdashti F et al (2008) Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 71:180-186 (Pubitemid 351492591)
44. Seol YM, Kwon BR, Song MK et al (2010) Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 49(2):201-208
45. Spiro SG, Buscombe J, Cook G et al (2008) Ensuring the right PET scan for the right patient. Lung Cancer 59:48-56
46. 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 49(11):1783-1789
47. 18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 80(2):151-156
48. 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol 192(4):W156-W160
49. van Tinteren H, Hoekstra OS, Smit EF et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359:1388-1393
50. Wieder HA, Beer AJ, Lordick F et al (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46:2029-2034 (Pubitemid 46657450)
51. 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 21(5):1078-1082
52. 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 136(6):883-889
53. 18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancera long-term outcome report. Int J Radiat Oncol Biol Phys 74(1):9-14
54. 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma. J Nucl Med 46(5):770-774
55. 18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 65(5):1307-1314